Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.
Non-Executive Chair Susan Foden says: "I am very pleased to welcome Toni in as permanent CFO and I look forward to working with him on the board. Toni's broad company experience is already making a difference to Evgen and he is providing considerable support to the rest of the executive team in driving projects forward."
Current stock price: 1.50 pence
12-month change: down 67%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
